Clinical Trial Update: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three regimens for endometrial cancer: paclitaxel-carboplatin-bevacizumab, paclitaxel-carboplatin-temsirolimus, and ixabepilone-carbopl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Adenosquamous Carcinoma
• Endometrial Cancer
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Malignant Uterine Corpus Neoplasm
• Uterine Carcinosarcoma
• Uterine Corpus Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Ixabepilone (ixabepilone)
• PACLITAXEL (PACLITAXEL)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-02-27